This article was originally published in The Gray Sheet
Executive SummaryResults of a 100-patient trial of Cardica's C-Port distal anastomosis system for cardiac bypass are presented by Michael Mack, MD, Cardiothoracic Surgery Associates of North Texas at the European Association for Cardiothoracic Surgery/European Society of Thoracic Surgeons joint meeting in Leipzig, Germany Sept. 13. Patency of bypass vessels attached with C-Port was 96.9% after six months, compared to 84.9% in historical studies. Cardica, which is 20% owned by Guidant, will use the data to support a CE mark and 510(k) indication in the coming months, the firm says...
You may also be interested in...
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.
Consumer health product firms say the coronavirus will have an impact on their results, but it’s too early to estimate the costs. US FDA also hedges its predictions, saying the outbreak could lead to interruptions in country’s drug and medical device supplies. China's health commission has issued six guidelines for diagnosis and treatment, but no conventional antiviral treatment is approved and it's emphasizing traditional Chinese medicines.
With less than one hundred days left before the European Union Medical Device Regulations kick in, Medtech Insight’s executive editor Ashley Yeo and managing editor Amanda Maxwell discuss growing concerns by medtech industry members that they may not be ready in time to comply with these regulations and may inadvertently go afoul of the new regulations.